BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12556647)

  • 21. [ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
    Kuwajima I
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():648-53. PubMed ID: 15171450
    [No Abstract]   [Full Text] [Related]  

  • 22. Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Scott I; Stowasser M
    Intern Med J; 2003 Jul; 33(7):327-30. PubMed ID: 12823686
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
    Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [ALLHAT: Old Hat Hits All? On selection of the optimal antihypertensive drug].
    Slany J
    Wien Klin Wochenschr; 2003 Mar; 115(5-6):149-51. PubMed ID: 12741071
    [No Abstract]   [Full Text] [Related]  

  • 25. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
    Phillips W; Piller LB; Williamson JD; Whittle J; Jafri SZ; Ford CE; Einhorn PT; Oparil S; Furberg CD; Grimm RH; Alderman MH; Davis BR; Probstfield JL;
    J Clin Hypertens (Greenwich); 2013 Nov; 15(11):825-32. PubMed ID: 24283598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
    J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Heidenreich PA; Davis BR; Cutler JA; Furberg CD; Lairson DR; Shlipak MG; Pressel SL; Nwachuku C; Goldman L
    J Gen Intern Med; 2008 May; 23(5):509-16. PubMed ID: 18228109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
    Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial.
    Wang SY; Hanna JM; Gongal P; Onuma OK; Nanna MG
    Am Heart J; 2022 Dec; 254():30-34. PubMed ID: 35932912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recommendations for the management of special populations: racial and ethnic populations.
    Ferdinand KC
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):50S-54S. PubMed ID: 14625162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Ernst ME; Davis BR; Soliman EZ; Prineas RJ; Okin PM; Ghosh A; Cushman WC; Einhorn PT; Oparil S; Grimm RH;
    J Am Soc Hypertens; 2016 Dec; 10(12):930-938.e9. PubMed ID: 27938852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure.
    Vidt DG
    Cleve Clin J Med; 2003 Mar; 70(3):263-9. PubMed ID: 12678218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
    Cushman WC; Ford CE; Cutler JA; Margolis KL; Davis BR; Grimm RH; Black HR; Hamilton BP; Holland J; Nwachuku C; Papademetriou V; Probstfield J; Wright JT; Alderman MH; Weiss RJ; Piller L; Bettencourt J; Walsh SM;
    J Clin Hypertens (Greenwich); 2002; 4(6):393-404. PubMed ID: 12461301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
    Haywood LJ; Davis BR; Piller LB; Cushman WC; Cutler JA; Ford CE; Simpson LM; Ghosh A; Soliman EZ; Wright JT;
    J Natl Med Assoc; 2017 Autumn; 109(3):172-181. PubMed ID: 28987246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
    Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
    Piller LB; Simpson LM; Baraniuk S; Habib GB; Rahman M; Basile JN; Dart RA; Ellsworth AJ; Fendley H; Probstfield JL; Whelton PK; Davis BR;
    J Gen Intern Med; 2014 Nov; 29(11):1475-83. PubMed ID: 25002161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber MA; Franklin S; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T;
    Ann Intern Med; 2006 Feb; 144(3):172-80. PubMed ID: 16461961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diuretics are better first-line antihypertensive therapy than calcium channel blockers and ACE inhibitors.
    Rollins G
    Rep Med Guidel Outcomes Res; 2003 Jan; 14(2):5-7. PubMed ID: 12776699
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.